Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
According to Novo Nordisk's latest financial reports the company's current earnings (TTM) are HK$131.37 B. In 2023 the company made an earning of HK$120.27 B an increase over its 2022 earnings that were of HK$76.29 B.The earnings displayed on this page is the company's Pretax Income.